Regencell Bioscience (RGC) Stock Price, News & Analysis

Company Overview

Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM)-based treatments for neurological and neurocognitive disorders. The company’s research is centered on formulations intended to address conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), as well as other disorders affecting brain function.

Regencell’s product candidates include RGC-M001, a proprietary TCM formulation being developed for ADHD and ASD, and RGC-M002, a formulation being investigated for dementia-related conditions. The company’s approach combines traditional Chinese medicine principles with research and clinical development intended to evaluate the safety and potential effectiveness of its treatments.

Regencell is based in Hong Kong and conducts its development activities through research and clinical initiatives in the region. The company was founded by Yat-Gai Au, who serves as its chief executive officer. Regencell completed its initial public offering on the Nasdaq Capital Market in 2021 and remains focused on advancing its TCM-based product candidates through development.

Key Stats

• Today's Range: $5.75 to $6.10
• 50-Day Range: $4.78 to $6.89
• 52-Week Range: $4.51 to $69.00
• Volume: 94,042 shs
• Average Volume: 172,286 shs
• Market Capitalization: $2.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Regencell Bioscience Stock Analysis - MarketRank™

Regencell Bioscience scored higher than 3% of companies evaluated by MarketBeat, and ranked 883rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Regencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Regencell Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Regencell Bioscience has a P/B Ratio of 579.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the float of Regencell Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Regencell Bioscience has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Regencell Bioscience has recently decreased by 3.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regencell Bioscience does not currently pay a dividend.

Dividend Growth

Regencell Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for RGC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regencell Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.00% of the stock of Regencell Bioscience is held by insiders.

Percentage Held by Institutions

0.13% of the stock of Regencell Bioscience is held by institutions.

Company Calendar

• Today: 9/19/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RGC
• Previous Symbol: NASDAQ:RGC
• CIK: 1829667
• Web: regencellbioscience.com
• Phone: 852 2155 0823
• Fax: 852-2155-0853
• Employees: 10
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.41
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 579.00

Miscellaneous

• Outstanding Shares: 494,490,000
• Free Float: 484,599,000
• Market Cap: $2.86 billion
• Optionable: N/A
• Beta: 1.45